BioMarin Pharmaceutical Inc. [NASDAQ: BMRN] stock went on a downward path that fall over -9.59% on Monday, amounting to a one-week price decrease of less than -5.86%. The company report on January 11, 2021 that BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set.
– Significantly Reduced Mean Annualized Bleeding Rate by 84% (p-value <0.0001) Demonstrating Superiority to Factor VIII Prophylaxis, and Reduced Mean Annualized Factor VIII Infusion Rate by 99% (p-value <0.0001). - Mean Factor VIII Expression 42.9 IU/dL at One Year in Full Study Population. Over the last 12 months, BMRN stock dropped by -10.82%. The one-year BioMarin Pharmaceutical Inc. stock forecast points to a potential upside of 26.25. The average equity rating for BMRN stock is currently 2.10, trading closer to a bullish pattern in the stock market. The market cap for the stock reached $14.88 billion, with 181.14 million shares outstanding and 180.42 million shares in the current float. Compared to the average trading volume of 1.42M shares, BMRN stock reached a trading volume of 4401005 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on BioMarin Pharmaceutical Inc. [BMRN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMRN shares is $110.15 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMRN stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for BioMarin Pharmaceutical Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on August 20, 2020. While these analysts kept the previous recommendation, Citigroup raised their target price from $148 to $86. The new note on the price target was released on August 20, 2020, representing the official price target for BioMarin Pharmaceutical Inc. stock. Previously, the target price had yet another drop from $127 to $100, while Stifel kept a Hold rating on BMRN stock.
The Average True Range (ATR) for BioMarin Pharmaceutical Inc. is set at 3.25, with the Price to Sales ratio for BMRN stock in the period of the last 12 months amounting to 7.99. The Price to Book ratio for the last quarter was 3.63, with the Price to Cash per share for the same quarter was set at 8.22. Price to Free Cash Flow for BMRN in the course of the last twelve months was 676.54 with Quick ratio for the last quarter at 2.40.
BMRN Stock Performance Analysis:
BioMarin Pharmaceutical Inc. [BMRN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.86. With this latest performance, BMRN shares gained by 6.67% in over the last four-week period, additionally sinking by -34.69% over the last 6 months – not to mention a drop of -10.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMRN stock in for the last two-week period is set at 42.22, with the RSI for the last a single of trading hit 35.52, and the three-weeks RSI is set at 45.91 for BioMarin Pharmaceutical Inc. [BMRN]. The present Moving Average for the last 50 days of trading for this stock 80.88, while it was recorded at 87.09 for the last single week of trading, and 92.89 for the last 200 days.
Insight into BioMarin Pharmaceutical Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and BioMarin Pharmaceutical Inc. [BMRN] shares currently have an operating margin of -6.75 and a Gross Margin at +75.51. BioMarin Pharmaceutical Inc.’s Net Margin is presently recorded at -1.41.
Return on Total Capital for BMRN is now -2.91, given the latest momentum, and Return on Invested Capital for the company is -0.64. Return on Equity for this stock declined to -0.78, with Return on Assets sitting at -0.52. When it comes to the capital structure of this company, BioMarin Pharmaceutical Inc. [BMRN] has a Total Debt to Total Equity ratio set at 29.13. Additionally, BMRN Total Debt to Total Capital is recorded at 22.56, with Total Debt to Total Assets ending up at 19.39. Long-Term Debt to Equity for the company is recorded at 17.20, with the Long-Term Debt to Total Capital now at 13.32.
Reflecting on the efficiency of the workforce at the company, BioMarin Pharmaceutical Inc. [BMRN] managed to generate an average of -$7,947 per employee. Receivables Turnover for the company is 4.68 with a Total Asset Turnover recorded at a value of 0.37.BioMarin Pharmaceutical Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 3.20.
BMRN Stock EPS
With the latest financial reports released by the company, BioMarin Pharmaceutical Inc. posted 0.08/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 233.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioMarin Pharmaceutical Inc. go to 47.54%.
BioMarin Pharmaceutical Inc. [BMRN] Insider Position Details
There are presently around $14,410 million, in the hands of institutional investors. The top three institutional holders of BMRN stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 22,063,262, which is approximately -0.011% of the company’s market cap and around 0.30% of the total institutional ownership; PRIMECAP MANAGEMENT CO/CA/, holding 18,191,541 shares of the stock with an approximate value of $1.48 billion in BMRN stocks shares; and VANGUARD GROUP INC, currently with $1.33 billion in BMRN stock with ownership of nearly -3.447% of the company’s market capitalization.
Positions in BioMarin Pharmaceutical Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 242 institutional holders increased their position in BioMarin Pharmaceutical Inc. [NASDAQ:BMRN] by around 22,960,528 shares. Additionally, 274 investors decreased positions by around 24,463,094 shares, while 61 investors held positions by with 129,957,010 shares. The mentioned changes placed institutional holdings at 177,380,632 shares, according to the latest SEC report filing. BMRN stock had 60 new institutional investments in for a total of 3,596,578 shares, while 91 institutional investors sold positions of 4,523,210 shares during the same period.